Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone

Blood

Volumn 92, Issue 4, 1998, Pages 1184-1190

  Davis, Thomas A ^b   Maloney, David G ^b   Czerwinski, Debra K ^b   Liles, Tina Marie ^b   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIIDIOTYPIC ANTIBODY; CHLORAMBUCIL; DNA; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN IDIOTYPE; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PROTEIN BCL 2;

ARTICLE; B CELL LYMPHOMA; CHROMOSOME 14; CHROMOSOME 18; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION;

EID: 0032529703     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.4.1184.416k05_1184_1190     Document Type: Article

References (42)

1. Levy R, Miller R: Therapy of lymphoma directed at idiotypes. J Natl Cancer Inst Monographs 10:61, 1990
2. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM: Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63:1424, 1984
3. Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. N EngI J Med 306:517, 1982
4. Brown SL, Miller RA, Horning SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R: Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 73:651, 1989
5. Brown S, Miller R, Levy R: Antiidiotype antibody therapy of B-cell lymphoma. Semin Oncol 16:199, 1989
6. Maloney D, Brown S, Czerwinski D, Liles TM, Man S, Miller R, Levy R: Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype negative variant cells. Blood 80:1502, 1992
7. Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Wamke R, Levy R: A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65:1349, 1985
8. Hatzubai A, Maloney D, Levy R: The use of a monoclonal anti-idiotype antibody to study the biology of a human B cell lymphoma. J Immunol 126:2397, 1981
9. Miller RA, Hart S, Samoszuk M, Coulter C, Brown S, Czerwinski D, Kelkenberg J, Royston I, Levy R: Shared idiotypes expressed by human B-cell lymphomas. N Engl J Med 321:851, 1989
10. Meeker T, Lowder J, Cleary ML, Stewart S, Warnke R, Sklar J, Levy R: Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med 312:1658, 1985
11. Gribben JG, Freedman A, Woo SD, Blake K, Shu RS, Freeman G, Longtine JA, Pinkus GS, Nadler LM: All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78:3275, 1991
12. Stetlet-Stevenson M, Raffeld M, Cohen P, Cossman J: Detection of occult follicular lymphoma by specific DNA amplification. Blood 72:1822, 1988
13. Yamada M, Hudson S, Tournay O, Bittenbender S, Shane S, Lange B, Tsujimoto Y, Caton A, Rovera G: Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using CDR3 specific probes. Proc Natl Acad Sci USA 86:5123, 1989
14. Pollard P, Owen G, Worwood M: PCR-based immunogenotyping at the Ig heavy chain CDR3 locus: Improvements in resolution. Br J Haematol 84:169, 1993
15. Linke B, Pyttlich J, Tiemann M, Suttorp M, Parwaresch R, Hiddemann W, Kneba M: Identification and structural analysis of rearranged immunoglobulin heavy chain genes in lymphomas and leukemias. Leukemia 9:840, 1995
16. Gribben JG, Neuberg D, Freedman AS, Gimmi CD, Pesek KW, Barber M, Saporito L, Woo SD, Coral F, Spector N, Rabinowe SN, Grossbard ML, Ritz J, Nadler LM: Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81:3449, 1993
17. Gribben JG, Neuberg D, Barber M, Moore J, Pesek KW, Freedman AS, Nadler LM: Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 83:3800, 1994
18. Steward CG, Potter MN, Oakhill A: Third complementarity determining region (CDR III) sequence analysis in childhood B-lineage acute lymphoblastic leukaemia: Implications for the design of oligo-nucleotide probes for use in monitoring minimal residual disease. Leukemia 6:1213, 1992
19. Vuist WM, Levy R, Maloney DG: Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood 83:899, 1994
20. Ishigami T, Kim KM, Horiguchi Y, Higaki Y, Hata D, Heike T, Katamura K, Mayumi M, Mikawa H: Anti-IgM antibody-induced cell death in a human B lymphoma cell line, B104, represents a novel programmed cell death. J Immunol 148:360, 1992
21. Benhamou LE, Cazenave PA, Sarthou P: Anti-immunoglobulins induce death by apoptosis in WEHI-231 B lymphoma cells. Eur J Immunol 20:1405, 1990
22. Sefton BM, Campbell MA: The role of tyrosine protein phosphorylation in lymphocyte activation. Annu Rev Cell Biol 7:257, 1991
23. Hasbold J, Klaus GG: Anti-immunoglobulin antibodies induce apoptosis in immature B cell lymphomas. Eur J Immunol 20:1685, 1990
24. Renschler MF, Bhatt RR, Dower WJ, Levy R: Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma. Proc Natl Acad Sci USA 91:3623, 1994
25. Uhr JW, Scheuermann RH, Street NE, Vitetta ES: Cancer dormancy: Opportunities for new therapeutic approaches. Nat Med 3:505, 1997
26. Uhr JW, Marches R, Racila E, Tucker TF, Hsueh R, Street NE, Vitetta ES, Scheuermann RH: Role of antibody signaling in inducing tumor dormancy. Adv Exp Med Biol 406:69, 1996
27. Racila E, Scheuennann R, Picker L, Yefenof E, Tucker T, Chang W, Marches R, Street N, Vitetta E, Uhr J: Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice. J Exp Med 181:1539, 1995
28. Yefenof E, Picker L, Scheuermann R, Tucker T, Vitteta E, Uhr J: Cancer Dormancy: Isolation and characterization of dormant lymphoma cells. Proc Natl Acad Sci USA 90:1829, 1992
29. Vitteta E, Tucker T, Racila E, Huang Y, Marches R, Lane N, Scheuermann R, Street N, Watanabe T, Uhr J: Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established. Blood 89:4425, 1997
30. Marches R, Racila E, Tucker TF, Picker L, Mongini P, Hsueh R, Vitetta ES, Scheuermann RH, Uhr JW: Tumour dormancy and cell signalling - III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. Ther Immunol 2:125, 1995
31. Wasserman R, Galili N, Ito Y, Silber J, Reichard B, Shane S, Womer R, Lange B, Rovera G: Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage ALL. J Clin Oncol 10:1879, 1992
32. McLaughlin P, Hagemeister FB, Swan F, Cabanillas F, Romaguera J, Rodriguez MA, Lee MS, Pate O, Sarris A, Younes A: Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: High remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol 5:73, 1994 (suppl 2)
33. Finke J, Slanina J, Lange W, Dolken G: Persistence of circulating t(14;18)-positive cells in long-term remission after radiation therapy for localized-stage follicular lymphoma. J Clin Oncol 11:1668, 1993
34. Roberts W, Estrov Z. Ouspenskaia M, Johnston D, McClain K, Zipf T: Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 336:317, 1997
35. Ha C, Cabanillas F, Lee M, Besa P, McLaughlin P, Cox J: Serial determination of the bcl-2 gene in the bone marrow and peripheral blood after central lymphatic irradiation for stages I-III follicular lymphoma: A preliminary report. Clin Cancer Res 3:215, 1997
36. Limpens J, de long D, van Krieken JH, Price CG, Young BD, van Ommen GJ, Kluin PM: Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene 6:2271, 1991
37. Limpens J, Stad R, Vos C, de Vlaam C, de long D, van Ommen GJ, Schuuring E, Kluin PM: Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 85:2528, 1995
38. Dolken G, Illerhaus G, Hirt C, Mertelsmann R: BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol 14:1333, 1996
39. Levy R, Levy S, Cleary M, Carroll W, Kon S, Bird J, Sklar J: Somatic mutation in human B cell tumors. Immunol Rev 96:43, 1987
40. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1992
41. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 89:3129, 1997
42. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52, 1996